August 01, 2019
Global liquid biopsy market is anticipated to reach US $3,051.1 million by 2025, according to the latest research available at Market Study Report LLC, report provides extensively data on market share, growth, trends and forecasts for the period 2018-2025.
Liquid Biopsy (also known as fluid phase biopsyor fluid biopsy) is a technique used to diagnose cancer at an early stage. It is mostly a non-invasive technique which helps in accurate tracking of mutations and tumors over a certain period. Using liquid biopsy doctors can gain a wide range of information regarding a tumor's future.
As per the study, increasing cases of patients being detected with numerous types of cancer is driving liquid biopsy market growth. Moreover, increasing number of free trails coupled with surging demand for minimal invasive liquid biopsy procedures are expected to expand market size over the forecast period.
Liquid biopsy is also observed to be a rapidly growing substitute for tissue biopsy, mostly due to reduced number of surgical invasions. Moreover, the growing trend of strategic mergers and acquisitions by key players to support R&D activities is positively impacting industry outlook, cites the study.
Based on technology type, the global liquid biopsy market comprises of single gene analysis (PCR Microarray), and multi-gene-parallel analysis (next-generation sequencing). Basically, NGS multiplex testing helps in diagnosis of multiple medical conditions at a single time, while PCR allows doctors to analyze gene mutation.
In terms of sample type, the market is segmented into saliva, blood, urine, and other body fluid. For the record, blood samples are the most popular sample type used by doctors to properly analyze blood samples containing circulating cell, cell-free DNA, and exosomes which eventually helps in easy diagnosis of the cancer cells in the body. In addition to this, saliva and other body fluids are also sampling types that hold substantial market share.
According to the report, in terms of biomarker type, CTC biomarker is anticipated hold the largest market share mainly due to factors like growing awareness and effective results for tracking cancer cells in the body. Reportedly, in 2017, CTC segment recorded the highest market share in terms of revenue. Moreover, it effectively enables early detection of cancer cells that can further help in proper diagnosis and clinical decisions related to cancer detection in its early stage.
Request sample copy of this Report@ https://www.marketstudyreport.com/request-a-sample/1695266/
According to regional analysis, North America is estimated to hold the highest share in global liquid biopsy market over the forecast period. Factors like increasing accessibility for cancer diagnosis and rising number of patients suffering from cancer in the region will boost market size. Additionally, Asia Pacific liquid biopsy market is also estimated to grow rapidly in the forecast timeframe.
The leading players operating in liquid biopsy market include Illumina, Inc., RainDance Technologies, Inc., Roche Diagnostics, Bio-Rad Laboratories Inc., Menarini Silicon Biosystems, Trovagene, Inc., Myriad Genetics, Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., Biocept, Inc., Genomic Health, Inc., MDxHealth SA, and Guardant Health, Inc. The company profiles of these industry behemoths are mentioned in the report alongside their product benchmarking, business overview, financials, and recent developments.